DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for mixed liposarcoma — screening already-approved drugs against its 43-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMixed liposarcoma maps to a 43-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedSunitinibApproved drug
Structures already discussed alongside mixed liposarcoma in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
KIT kinase domain — Sunitinib has a real, experimentally solved structure in complex with this target (PDB 3G0E, 1.6 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet b49drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3G0E · 1.6 Å · ligand Sunitinib (B49). Experimental structure, not a prediction.
What the evidence adds up to
The 2012 retrospective study of eleven primary oral and maxillofacial liposarcomas, treated at a Chinese tertiary referral centre between 1993 and 2009, included two cases of mixed-type liposarcoma. Among the whole cohort, eight patients were female and three male, aged 8 to 76 years. All patients underwent surgery alone or with postoperative radiotherapy; two patients had been misdiagnosed and inappropriately treated before referral and developed local relapse. Over a mean follow-up of 4.5 years (range 1–11 years), no distant metastases were recorded and there was one disease-related death. The authors recommend complete excision with negative margins and long-term follow-up as the treatment of choice.
A 2008 case report describes a 50-year-old man with a retroperitoneal mixed-type liposarcoma composed of four histologically different subtypes, an extremely rare finding. A 2019 case report of a dedifferentiated pancreatic liposarcoma in a young female, the seventh pancreatic liposarcoma in the English literature and the third dedifferentiated one, notes that the patient declined postoperative chemotherapy after surgery and was well with no relapse at 26 months. That report states that complete resection is the only effective treatment and that chemotherapy should be included in treatment regimens, though it provides no data on chemotherapy efficacy in this patient.
Two 2024 reviews and a 2025 bibliometric analysis summarise the molecular landscape of liposarcoma. The 2024 review on genetic, epigenetic and transcriptome alterations states that surgical resection remains the mainstay for localised disease across all subtypes, and that many patients present with or progress to unresectable, metastatic or both advanced disease. It reports that the most promising targeted therapy results have been shown for CDK4/6 and MDM2 inhibitors, and for the multi-kinase inhibitors anlotinib and sunitinib, but provides no response rates or survival figures. The bibliometric analysis of publications from 2004 to 2023 notes a shift from surgical resection to multidisciplinary therapy, with high-frequency keywords including trabectedin and radiotherapy, and high-frequency genes including TP53, MDM2, CDK4, DDIT3 and CD274. It offers no efficacy data.
Across these abstracts, there is no clinical trial evidence for any drug specifically in mixed-type liposarcoma. The only concrete outcome data come from small surgical case series, where surgery with negative margins is the sole intervention associated with long-term disease control. What is missing is prospective trial data for targeted agents in this rare subtype, reliable patient stratification by molecular markers such as MDM2 and CDK4 amplification, and any randomised comparison of systemic therapy against surgery alone or observation. Without such evidence, claims of benefit for any drug in mixed-type liposarcoma remain unsupported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Medical Science · 2012 · 24 citations · open access
Primary oral and maxillofacial liposarcoma: a clinicopathological and immunohistochemical study of eleven cases
AbstractINTRODUCTION: The present study was aimed to characterize the clinicopathological, immunohistochemical features and treatment outcomes of primary oral and maxillofacial liposarcomas by presenting the experience over a 16-year period at a tertiary referral Chinese institution for head neck cancer. MATERIAL AND METHODS: This retrospective clinical study included 11 cases of pathologically confirmed primary liposarcomas treated from January 1993 to September 2009. Detailed information regarding primary site, clinical manifestations, histopathological and immunohistochemical analysis, treatments and prognosis was collected and reported. RESULTS: Eight female and 3 male patients aged from 8 to 76 years old. These lesions occurred in buccal (3), parotid (2), temporal (2), tongue (2), palate (1) and oropharyngeal (1) region. They were histopathologically categorized into 4 subtypes based on WHO classification scheme: atypical lipomatous tumor/well-differentiated (4), myxoid (4), mixed-type (2) and pleomorphic (1) liposarcomas. Immunohistochemical staining indicated mostly positive for Vimentin and S-100 but negative for other markers. Most patients presented as slow-growing painless masses and underwent surgery alone or combined with postoperative radiotherapy. Two patients were misdiagnosed and inappropriate treated and developed local relapse before referred to our institute. No distant metastasis and one disease-related death were recorded during the follow-up (ranging: 1-11 years, mean: 4.5 years). CONCLUSIONS: Oral and maxillofacial liposarcoma is exceedingly rare and has atypical clinical manifestations but characteristic histopathology. Complete excision with negative margins followed by long-term follow-up is recommended as the treatment of choice for these uncommon entities.
Retroperitoneal Mixed-Type Liposarcoma Showing Features of Four Different Subtypes
AbstractMixed-type liposarcoma is a rare soft tissue tumor. This report describes a 50-year-old man with retroperitoneal mixed-type liposarcoma that consisted of four pathologically different components. Preoperative CT and MRI showed a giant retroperitoneal mass composed of several nodules with various attenuation and signal intensity. At laparotomy, the tumor appeared to be composed of four components. Pathologic examination revealed that each component was of a histologically different subtype. Mixed-type liposarcoma containing four different subtypes is extremely rare. Its clinical and pathologic features are briefly reviewed.
World Journal of Clinical Cases · 2019 · 11 citations · open access
Huge primary dedifferentiated pancreatic liposarcoma mimicking carcinosarcoma in a young female: A case report
AbstractBACKGROUND: Pancreatic liposarcoma is a rare tumor. According to a literature review, the patient described in this study is the seventh case of pancreatic liposarcoma reported in the English literature and the third case of dedifferentiated liposarcoma. Furthermore, this case had the largest primary tumor volume, and a primary pancreatic liposarcoma was diagnosed based on sufficient evidence. CASE SUMMARY: gene amplification, the tumor was diagnosed as a dedifferentiated liposarcoma. The patient was treated with surgery but declined postoperative chemotherapy. She was well at the 26-mo follow-up, and no relapse was observed. CONCLUSION: Pancreatic liposarcoma has a low incidence. Chemotherapy should be included in the treatment regimens. Complete resection is the only effective treatment.
Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection
AbstractLiposarcoma (LPS) is one of the most common adult soft-tissue sarcomas (STS), characterized by a high diversity of histopathological features as well as to a lesser extent by a spectrum of molecular abnormalities. Current targeted therapies for STS do not include a wide range of drugs and surgical resection is the mainstay of treatment for localized disease in all subtypes, while many LPS patients initially present with or ultimately progress to advanced disease that is either unresectable, metastatic or both. The understanding of the molecular characteristics of liposarcoma subtypes is becoming an important option for the detection of new potential targets and development novel, biology-driven therapies for this disease. Innovative therapies have been introduced and they are currently part of preclinical and clinical studies. In this review, we provide an analysis of the molecular genetics of liposarcoma followed by a discussion of the specific epigenetic changes in these malignancies. Then, we summarize the peculiarities of the key signaling cascades involved in the pathogenesis of the disease and possible novel therapeutic approaches based on a better understanding of subtype-specific disease biology. Although heterogeneity in liposarcoma genetics and phenotype as well as the associated development of resistance to therapy make difficult the introduction of novel therapeutic targets into the clinic, recently a number of targeted therapy drugs were proposed for LPS treatment. The most promising results were shown for CDK4/6 and MDM2 inhibitors as well as for the multi-kinase inhibitors anlotinib and sunitinib.
Frontiers in Oncology · 2024 · 5 citations · open access
Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities
AbstractIn recent years, an increasing number of studies have utilized molecular biology techniques to reveal important molecular heterogeneity among different subtypes of liposarcoma. Each subtype exhibits distinct genetic patterns and molecular pathways, which may serve as important targets for molecular therapy. In the present review, we focus on the molecular characteristics, molecular diagnostics, driver genes, and molecular mechanisms of liposarcoma. We also discuss the clinical research progress of related targeted therapies, with an aim to provide a reference and crucial insights for colleagues in the field.
Oncology in Clinical Practice · 2019 · 3 citations · open access
Liposarcoma — spectrum of disease
AbstractLiposarcomas are the most common soft tissue sarcomas in adults. Diagnosis and treatment of liposarcoma should always be planned and conducted in centres experienced in the treatment of these heterogeneous malignancies with different prognosis and sensitivity to the treatment used. In the following paper, we present a summary of current knowledge about liposarcomas considering the differences between subtypes and new directions in treatment.
Journal of Cancer Research and Clinical Oncology · 2025 · 2 citations · open access
Bibliometric analysis of liposarcomas treatment from 2004 to 2023
AbstractBACKGROUND: Liposarcomas are mesenchymal malignant tumors characterized by varying degrees of adipocytic differentiation that comprises approximately 20% of soft tissue sarcomas. Despite advancements in this field, there remains a need for a comprehensive understanding of the mechanisms, diagnosis, and treatment of liposarcomas. Currently, there is a lack of bibliometric surveys on the development trajectory of liposarcomas treatment, research hotspots, and author and team collaboration. METHODS: In this study, we obtained publications from the Web of Science database from 2004 to 2023, with a specific focus on the treatment of liposarcomas. By utilizing bibliometric methods, the data were processed to facilitate visual analysis of various aspects, including authors, countries, institutions, cocitations, keywords, references, and gene characteristics. RESULTS: The number of publications on liposarcomas treatment has increased over the past two decades, from 39 in 2004 to 232 in 2023, with the United States of America contributing the most publications. Among the institutions, the Memorial Sloan Kettering Cancer Center had the highest volume of 87 publications. Notably, Alessandro Gronchi published 63 articles on the treatment of liposarcomas in the last 20 years. Cancers is the journal with the highest number of 57 publications. High-frequency keywords in these publications included "soft tissue sarcoma", "liposarcoma", "retroperitoneal sarcoma", "surgery", "dedifferentiated liposarcoma", "trabectedin" and "radiotherapy". Recent trends, identified through strong citation bursts from 2020 to 2023, include next-generation sequencing, radiotherapy, and patient-derived cell lines. High-frequency genes in the liposarcomas treatment field include TP53, MDM2, CDK4, DDIT3, and CD274. CONCLUSIONS: The treatment of liposarcomas has garnered increasing attention worldwide in the last 20 years. The treatment approach has shifted from surgical resection to multidisciplinary therapy. The molecular and biological characteristics of different tumor subtypes have attracted more research attention, providing an important reference for the choice of treatment. The findings of this study contribute to providing a comprehensive understanding of liposarcomas treatment among researchers. Moreover, they offer valuable perspectives that can guide future research.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
